Suppr超能文献

毛利人中因甲状腺毒症心脏并发症导致的住院人数增加。

Increased Admissions Due to Cardiac Complications of Thyrotoxicosis in Māori.

作者信息

Tamatea Jade A U, Elston Marianne S, Conaglen John V

机构信息

Waikato Clinical Campus, University of Auckland, Hamilton, New Zealand.

Waikato Clinical Campus, University of Auckland, Hamilton, New Zealand.

出版信息

Heart Lung Circ. 2019 Feb;28(2):284-288. doi: 10.1016/j.hlc.2017.11.003. Epub 2017 Nov 21.

Abstract

BACKGROUND

As thyrotoxicosis is a risk factor for atrial fibrillation, current guidelines recommend measuring a thyroid-stimulating hormone level in patients with this disorder. Hyperthyroidism may also be associated with other heart diseases including cardiac ischaemia and cardiac failure. Currently, the prevalence of thyrotoxicosis in cardiac admissions in the absence of a rhythm disorder is unknown.

AIMS

The aims of this study were: 1) to calculate the prevalence of admissions for thyrotoxicosis-associated cardiac disease, 2) determine the type of cardiac disease i.e. dysrhythmic, ischaemic or cardiac failure, and 3) to assess whether Māori are over-represented amongst patients admitted to hospital with cardiac complications of thyrotoxicosis.

METHODS

A retrospective review of admissions with both thyrotoxicosis and cardiac disease from 1 January 2005 to 31 December 2012 inclusive.

RESULTS

Seventy-two patients were identified as being admitted for a cardiac complication of thyrotoxicosis, giving a mean of nine admissions per year. Dysrhythmia was the cause for admission in 32 patients, ischaemia in 12, cardiac failure in 11 and mixed cardiac disease in 17. Graves' disease and amiodarone-induced were the most common causes of the thyrotoxicosis (25 and 19 cases, respectively). Of the cohort 26 (36.1%) were Māori (compared to 16.8% of all cardiac admissions over the same period). Māori were more likely to present with cardiac failure than non-Māori (57.7% vs. 26.1%, p=0.008 respectively).

CONCLUSIONS

Māori are over-represented amongst patients admitted with cardiac complications of thyrotoxicosis and more often present with cardiac failure than non-Māori. Measurement of thyroid function should be considered in patients presenting not only with atrial fibrillation but also in patients presenting with cardiac failure, particularly if they are Māori.

摘要

背景

由于甲状腺毒症是心房颤动的一个危险因素,当前指南建议对患有该疾病的患者检测促甲状腺激素水平。甲状腺功能亢进症也可能与包括心肌缺血和心力衰竭在内的其他心脏病有关。目前,在没有心律失常的心脏科住院患者中甲状腺毒症的患病率尚不清楚。

目的

本研究的目的是:1)计算甲状腺毒症相关心脏病的住院患病率;2)确定心脏病的类型,即心律失常性、缺血性或心力衰竭性;3)评估在因甲状腺毒症心脏并发症入院的患者中毛利人是否占比过高。

方法

对2005年1月1日至2012年12月31日期间因甲状腺毒症和心脏病入院的病例进行回顾性研究。

结果

72例患者被确定因甲状腺毒症的心脏并发症入院,平均每年9例。32例患者因心律失常入院,12例因缺血,11例因心力衰竭,17例因混合性心脏病。格雷夫斯病和胺碘酮诱发是甲状腺毒症最常见的病因(分别为25例和19例)。在该队列中,26例(36.1%)为毛利人(同期所有心脏科住院患者中毛利人占16.8%)。与非毛利人相比,毛利人更易出现心力衰竭(分别为57.7%和26.1%,p=0.008)。

结论

在因甲状腺毒症心脏并发症入院的患者中毛利人占比过高,且与非毛利人相比,毛利人更常出现心力衰竭。对于不仅有心房颤动,而且有心力衰竭的患者,尤其是毛利人,应考虑检测甲状腺功能。

相似文献

2
Cardiothyreosis: Prevalence and risk factors.心肌甲状腺肿:患病率及危险因素。
Ann Endocrinol (Paris). 2019 Sep;80(4):211-215. doi: 10.1016/j.ando.2017.11.004. Epub 2019 Jun 21.
4
10
Thyrotoxicosis and the heart.
N Engl J Med. 1992 Jul 9;327(2):94-8. doi: 10.1056/NEJM199207093270206.

引用本文的文献

1
Cardiac manifestations in hyperthyroidism.甲状腺功能亢进症的心脏表现。
Rev Cardiovasc Med. 2022 Apr 11;23(4):136. doi: 10.31083/j.rcm2304136. eCollection 2022 Apr.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验